Replies to post #156597 on Biotech Values

[ciotera]

RE: GILD approval timing

I think the data for 7977+RBV in GT2/3 are expected sooner than 7977+IFN+RBV in GT1. So unless, GILD decides to delay the filing (which would be irrational), the first NDA should be for either GT2/3 combined or GT2 alone depending on how the FDA feels about the GT3 SVR.